Big Data Business Development DNA Life Science 
Drug Discovery World
SEPTEMBER 6, 2022
This will be driven in a major way through breadth of ongoing research and an increased move to better tolerated, logistically simpler allogeneic platforms, such as the optimized Natural Killer (NK) cell therapies being developed at ONK Therapeutics. Chris Nowers, CEO, ONK Therapeutics. . “ Víctor Cervera-Carrascón, Tilt Bio. .
XTalks
AUGUST 2, 2023
They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. 2022 Revenue: In 2022, Merck KGaA (Life Science and Healthcare divisions only) had an annual revenue of €18.22
Expert insights. Personalized for you.
52 
Let's personalize your content